Biosenta Inc.
ZRO
CNSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -33.33% | -22.22% | -53.85% | -23.08% | -99.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.33% | -22.22% | -53.85% | -23.08% | -99.17% |
| Cost of Revenue | -87.39% | -87.39% | 282.61% | 241.43% | -54.14% |
| Gross Profit | 90.00% | 90.00% | -362.50% | -303.51% | -140.35% |
| SG&A Expenses | 36.73% | 23.35% | 11.39% | -40.06% | -52.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.90% | 15.37% | 8.73% | -39.17% | -48.98% |
| Operating Income | -25.95% | -15.41% | -8.82% | 39.18% | 45.57% |
| Income Before Tax | -422.54% | -295.28% | 114.19% | 116.62% | 48.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -422.54% | -295.28% | 114.19% | 116.62% | 48.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -422.54% | -295.28% | 114.19% | 116.62% | 48.29% |
| EBIT | -25.95% | -15.41% | -8.82% | 39.18% | 45.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -381.99% | -215.50% | 128.45% | 126.85% | 68.71% |
| Normalized Basic EPS | -10.39% | 26.15% | 14.05% | 51.52% | 55.14% |
| EPS Diluted | -381.99% | -215.50% | 128.45% | 126.85% | 68.71% |
| Normalized Diluted EPS | -10.39% | 26.15% | 14.05% | 51.52% | 55.14% |
| Average Basic Shares Outstanding | 31.64% | 33.32% | 5.39% | 13.04% | 12.27% |
| Average Diluted Shares Outstanding | 31.64% | 33.32% | 5.39% | 13.04% | 12.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
